Predictive factors for non-compliance with antituberculosis therapy in patients infected with human immunodeficiency virus;Factores predictivos del abandono del tratamiento antituberculoso en pacientes infectados por el virus de la inmunodeficiencia humana

Revista Clinica Espanola

Volumn 197, Issue 3, 1997, Pages 163-166

  Pulido Ortega, F ^a   Pena Sanchez De Rivera J M ^b   Rubio Garcia R ^b   Gonzalez Garcia J ^b   Costa Perez Herrero J R ^a   Vazquez Rodriguez J J ^b   Del Palacio Perez Medel A ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

HIV infection; Therapy non compliance; Tuberculosis

Indexed keywords

ADULT; ARTICLE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; RISK; STATISTICS; TREATMENT REFUSAL; TUBERCULOSIS;

ADULT; FEMALE; HIV INFECTIONS; HUMANS; MALE; RISK; TREATMENT REFUSAL; TUBERCULOSIS;

EID: 0031090921     PISSN: 00142565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Rey R, Ausina V, Casal M, et al Situación actual de la tuberculosis en España Una perspectiva sanitaria en precario respecto a los paises desarrollados. Med Clín (Barc) 1995, 105.703-707.
2. Grupo de Estudio de Tuberculosis Resistente de Madrid Estudio transversal multihospitalario de tuberculosis y resistencias en Madrid (octubre de 1993-abril de 1994) Med Clín (Barc) 1996; 106:1-6
3. Daley CL, Small PM, Schecter GF, et al An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. N Engl J Med 1992, 326:231-235
4. Ackah AN, Coulibaly D, Digbeu H, et al. Response to treatment, mortality and CD4 lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan, Côte d'Ivoire. Lancet 1995, 345:607-610.
5. Parriéns JH, Louis ME, Mukadi YB, et al Pulmonary tuberculosis in HIV-infected patients in Zaire. A controlled trial of treatment for either 6 or 12 months. N Engl J Med 1995; 332:779-784
6. Small PM, Schecter GF, Goodman PC, Sande MA, Chaisson RE, Hopewell PC. Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. N Engl J Med 1991; 324.289-294.
7. Gaspar G, Gato A, Ballesteros P, Pérez Gómez V. Tasa de abandono de tratamiento en pacientes con tuberculosis e infección por VIH. An Med Interna 1992; 9:101-102.
8. Nolan CM Failure of therapy for tuberculosis in human immunodeficiency virus infection. Am J Med Sci 1992, 304:168-173.
9. Iseman MD, Cohn DL, Sbarbaro JA Directly observed treatment of tuberculosis We can't afford not to try it N Engl J Med 1993; 328:576-578.
10. Weiss JE, Slocum PC, Blaix FX, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994, 330.1.179-1.184.
11. Servicio de Salud Pública del Área 11 de Madrid. Registro de casos de tuberculosis en el área 11. Boletín de Indicadores del Sistema de Información Sanitana del Área 11. Madrid, 1995; 4 14.
12. Centers for Disease Control. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR Morb Mortal Wkly Rep 1987; 36 1S-15S
13. Doménech JM Métodos estadisticos en ciencias de la salud. Bellaterra: Editorial Signo, 1990.
14. Sumartojo E. When tuberculosis treatment fails. A social behaviural account of patient adherence. Am Rev Respir Dis 1993; 147:1.311-1.320.
15. Castelo A, Jardim JRB, Goihman S, et al Comparison of daily and twice-weekly regimens to treat pulmonary tuberculosis. Lancet 1989; 2 1.173-1.176
16. Cohn DL Catlin BJ, Peterson KL, Judson FN, Sbarbaro JA. A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis: a twice-weekly, direct observed and cost effective regimen. Ann Intern Med 1990, 112 405-407.
17. Combs DL, O Brien JO, Geiter LJ USPHS tuberculosis short course chemotherapy trial 21- effectiveness, toxicity and acceptability. The report of final results Ann Intern Med 1990; 112.397-406.
18. Snider DE, Graczyk J, Bek E, Rowoski J. Supervised six-months treatment of newly diagnosed pulmonary tuberculosis using isoniazid, rifampin and pyrazinamide with and without streptomycin. Am Rev Respir Dis 1984; 130 1.091-1.094
19. Alwood K, Keruly J, Moore-Rice K, Stanton DI, Chaulk CP, Chaisson RE Effectiveness of supervised, intermittent therapy for tuberculosis in HIV-infected patients AIDS 1994; 8.1 103-1 108
20. Rabanaque MJ, Tomás C, Gómez-López LI, Aibar C, Pérez de Agreda JP, Febrel I Costes hospitalarios en pacientes con infección por el virus de la inmunodeficiencia humana. Med Clín (Barc) 1992, 98:85-88
21. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellete VL How often is medication taken as prescribed? A novel assessment technique. JAMA 1989; 261 3.273-3.277
22. a ed). Boston: Little, Brown and Company, 1996, 927-934.
23. a ed). Baltimore: Williams & Wilkins, 1995; 259-282.
24. Curtis R, Friedman SR, Neaigus A, José B, Goldstein M. Des Jarlais DC Implications of directly observed therapy in tuberculosis control measures among IDUs. Public Health Rep 1994; 109 319-327.